Hans Peter Tony

Summary

Country: Germany

Publications

  1. ncbi Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and λ light chains
    Arumugam Palanichamy
    Department of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik II, Oberdürrbacherstr 6, 97080 Wurzburg, Germany
    J Rheumatol 39:1130-8. 2012
  2. ncbi Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients
    Stefan Bittner
    Department of Neurology, University of Wuerzburg, Josef Schneider Str 11, Wuerzburg 97080, Germany
    Arthritis Res Ther 13:R21. 2011
  3. ncbi Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
    Anne Sophie Rouzière
    Department of Medicine II, Rheumatology and Clinical Immunology, University of Wuerzburg, Germany
    Arthritis Res Ther 7:R714-24. 2005
  4. ncbi Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells
    Khalid Muhammad
    Medizinische Klinik und Poliklinik II, Division of Rheumatology Clinical Immunology, University of Wurzburg, Wurzburg, Germany
    Ann Rheum Dis 70:1507-10. 2011
  5. ncbi Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment
    Khalid Muhammad
    Medizinische Klinik II, Department of Rheumatology and Clinical Immunology, University of Wurzburg, Wurzburg, Germany
    Arthritis Rheum 60:2284-93. 2009
  6. ncbi Psoriatic arthritis: clinical spectrum and diagnostic procedures
    Stefan Kleinert
    Medizinische Klinik and Poliklinik II, Department of Rheumatology and Clinical Immunology, University of Wuerzburg, Klinikstrasse 6, D 97070 Wurzburg, Germany
    Clin Dermatol 25:519-23. 2007
  7. ncbi Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development
    Philipp Strobel
    Institute of Pathology, University of Wurzburg, Germany
    J Pathol 207:72-82. 2005
  8. ncbi Nucleoporin p62 antibodies in a case of mixed connective tissue disease
    Doris M Kraemer
    Medizinische Poliklinik, University of Wurzburg, 97070 Wurzburg, Germany
    Clin Diagn Lab Immunol 10:329-31. 2003
  9. ncbi Effective B cell depletion with rituximab in the treatment of autoimmune diseases
    Christian Kneitz
    Medizinische Poliklinik der Universität Würzburg, Germany
    Immunobiology 206:519-27. 2002
  10. ncbi Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study
    Martin Feuchtenberger
    Medizinische Klinik, Universität Wuerzburg, Schwerpunkt Rheumatologie Klinische Immunologie, Oberdürrbacherstrasse 6, 97080, Wuerzburg, Germany
    Rheumatol Int 32:1533-9. 2012

Collaborators

Detail Information

Publications13

  1. ncbi Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and λ light chains
    Arumugam Palanichamy
    Department of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik II, Oberdürrbacherstr 6, 97080 Wurzburg, Germany
    J Rheumatol 39:1130-8. 2012
    ..Although phenotypic repopulation kinetics of B cell subsets are well documented, precise molecular analyses of the reconstituting immunoglobulin (Ig) genes encoding the B cell receptor in RA are sparse...
  2. ncbi Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients
    Stefan Bittner
    Department of Neurology, University of Wuerzburg, Josef Schneider Str 11, Wuerzburg 97080, Germany
    Arthritis Res Ther 13:R21. 2011
    ..1 is upregulated upon (autoimmune) T cell stimulation. The aim of this study was to correlate expression levels of K(2P)5.1 on T cells from patients with rheumatoid arthritis (RA) to disease activity in these patients...
  3. ncbi Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
    Anne Sophie Rouzière
    Department of Medicine II, Rheumatology and Clinical Immunology, University of Wuerzburg, Germany
    Arthritis Res Ther 7:R714-24. 2005
    ..The longitudinal observation of a single patient up to 27 months shows subtle intraindividual changes, which may indicate repertoire modulation...
  4. ncbi Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells
    Khalid Muhammad
    Medizinische Klinik und Poliklinik II, Division of Rheumatology Clinical Immunology, University of Wurzburg, Wurzburg, Germany
    Ann Rheum Dis 70:1507-10. 2011
    ..As IL-6 is a late differentiation factor of B cells the authors asked if IL-6R inhibition impacts on the mutational differentiation of human memory B-cell antigen receptors in vivo...
  5. ncbi Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment
    Khalid Muhammad
    Medizinische Klinik II, Department of Rheumatology and Clinical Immunology, University of Wurzburg, Wurzburg, Germany
    Arthritis Rheum 60:2284-93. 2009
    ..This study was undertaken to determine whether mutational acquisition in individual B cell receptors in repopulating class-switched and non-class-switched memory B cells is affected by rituximab...
  6. ncbi Psoriatic arthritis: clinical spectrum and diagnostic procedures
    Stefan Kleinert
    Medizinische Klinik and Poliklinik II, Department of Rheumatology and Clinical Immunology, University of Wuerzburg, Klinikstrasse 6, D 97070 Wurzburg, Germany
    Clin Dermatol 25:519-23. 2007
    ..This article reviews the clinical spectrum and diagnostic procedures that can lead to the diagnosis of psoriatic arthritis...
  7. ncbi Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development
    Philipp Strobel
    Institute of Pathology, University of Wurzburg, Germany
    J Pathol 207:72-82. 2005
    ....
  8. ncbi Nucleoporin p62 antibodies in a case of mixed connective tissue disease
    Doris M Kraemer
    Medizinische Poliklinik, University of Wurzburg, 97070 Wurzburg, Germany
    Clin Diagn Lab Immunol 10:329-31. 2003
    ..Thus far, p62 antibodies have mainly been described in cases of primary biliary cirrhosis. We speculate that the presence of p62 antibodies is an indication of a poor prognosis in connective tissue disorders...
  9. ncbi Effective B cell depletion with rituximab in the treatment of autoimmune diseases
    Christian Kneitz
    Medizinische Poliklinik der Universität Würzburg, Germany
    Immunobiology 206:519-27. 2002
    ..Further studies are needed to assess the clinical benefit of B cell depletion in the treatment of autoimmune diseases...
  10. ncbi Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study
    Martin Feuchtenberger
    Medizinische Klinik, Universität Wuerzburg, Schwerpunkt Rheumatologie Klinische Immunologie, Oberdürrbacherstrasse 6, 97080, Wuerzburg, Germany
    Rheumatol Int 32:1533-9. 2012
    ..Nevertheless, there was a discrepancy between vaccination awareness and actual vaccination rates for all cohorts...
  11. ncbi Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study
    Stefan Kleinert
    Rheumatologie Klinische Immunologie, Universitatsklinikum Wurzburg, Medizinische Klinik und Poliklinik II, Oberdürrbacherstr 6, 97080 Wurzburg, Germany
    Rheumatol Int 32:2759-67. 2012
    ..Patients with high disease activity and low functional capacity are particularly benefitted by adalimumab therapy...
  12. ncbi Psoriatic arthritis: therapeutic principles
    Martin Feuchtenberger
    Medizinische Klinik and Poliklinik II, Department of Rheumatology and Clinical Immunology, University of Wurzburg, Klinikstrasse 6, D 97070 Wurzburg, Germany
    Clin Dermatol 26:460-3. 2008
    ..Substantial improvement in understanding immunopathology of PsA has led to a variety of new therapeutic options. This article reviews the current therapeutic principles for PsA...
  13. ncbi Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
    Hans Peter Tony
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Klinikstr 6 8, 97070 Wurzburg, Germany
    Arthritis Res Ther 13:R75. 2011
    ....